Search

Author/Creator Awada, Gil

1. A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors. Issue 3 (29th March 2022)

Authors:
Awada, Gil; Schwarze, Julia Katharina; Tijtgat, Jens; Fasolino, Giuseppe; Kruse, Vibeke; Neyns, Bart
Journal:
Melanoma research
Issue:
Volume 32:Issue 3(2022)
Page Start:
183
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. ATIM-38. GLITIPNI: A PHASE 1B CLINICAL TRIAL COMBINING SURGICAL RESECTION WITH DIRECT INTRACEREBRAL INJECTION OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH RECURRENT GLIOBLASTOMA. (11th November 2019)

Authors:
Duerinck, Johnny; Awada, Gil; Katharina Schwarze, Julia; Dufait, Ines; Peeters, Stephanie; Seynave, Laura; Van Binst, Anne-marie; Everaert, Hendrik; Michotte, Alex; Rogiers, Anne; Van Velthoven, Vera; Neyns, Bart
Journal:
Neuro-oncology
Issue:
Volume 21(2019)Supplement 6
Page Start:
vi10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Issue 2 (16th October 2020)

Authors:
Awada, Gil; Ben Salama, Laila; De Cremer, Jennifer; Schwarze, Julia Katharina; Fischbuch, Lydia; Seynaeve, Laura; Du Four, Stephanie; Vanbinst, Anne-Marie; Michotte, Alex; Everaert, Hendrik; Rogiers, Anne; Theuns, Peter; Duerinck, Johnny; Neyns, Bart
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Issue 2 (16th October 2020)

Authors:
Awada, Gil; Ben Salama, Laila; De Cremer, Jennifer; Schwarze, Julia Katharina; Fischbuch, Lydia; Seynaeve, Laura; Du Four, Stephanie; Vanbinst, Anne-Marie; Michotte, Alex; Everaert, Hendrik; Rogiers, Anne; Theuns, Peter; Duerinck, Johnny; Neyns, Bart
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Issue 2 (16th October 2020)

Authors:
Awada, Gil; Ben Salama, Laila; De Cremer, Jennifer; Schwarze, Julia Katharina; Fischbuch, Lydia; Seynaeve, Laura; Du Four, Stephanie; Vanbinst, Anne-Marie; Michotte, Alex; Everaert, Hendrik; Rogiers, Anne; Theuns, Peter; Duerinck, Johnny; Neyns, Bart
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Issue 2 (16th October 2020)

Authors:
Awada, Gil; Ben Salama, Laila; De Cremer, Jennifer; Schwarze, Julia Katharina; Fischbuch, Lydia; Seynaeve, Laura; Du Four, Stephanie; Vanbinst, Anne-Marie; Michotte, Alex; Everaert, Hendrik; Rogiers, Anne; Theuns, Peter; Duerinck, Johnny; Neyns, Bart
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Issue 2 (16th October 2020)

Authors:
Awada, Gil; Ben Salama, Laila; De Cremer, Jennifer; Schwarze, Julia Katharina; Fischbuch, Lydia; Seynaeve, Laura; Du Four, Stephanie; Vanbinst, Anne-Marie; Michotte, Alex; Everaert, Hendrik; Rogiers, Anne; Theuns, Peter; Duerinck, Johnny; Neyns, Bart
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Issue 2 (16th October 2020)

Authors:
Awada, Gil; Ben Salama, Laila; De Cremer, Jennifer; Schwarze, Julia Katharina; Fischbuch, Lydia; Seynaeve, Laura; Du Four, Stephanie; Vanbinst, Anne-Marie; Michotte, Alex; Everaert, Hendrik; Rogiers, Anne; Theuns, Peter; Duerinck, Johnny; Neyns, Bart
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx). Issue 2 (16th October 2020)

Authors:
Awada, Gil; Ben Salama, Laila; De Cremer, Jennifer; Schwarze, Julia Katharina; Fischbuch, Lydia; Seynaeve, Laura; Du Four, Stephanie; Vanbinst, Anne-Marie; Michotte, Alex; Everaert, Hendrik; Rogiers, Anne; Theuns, Peter; Duerinck, Johnny; Neyns, Bart
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8:Issue 2(2020)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗